Ophthalmology最新文献

{"title":"Embolus Migration and Reperfusion in Central Retinal Artery Occlusion Treated by Intra-Arterial Cannulation.","authors":"Shin Tanaka, Maiko Maruyama-Inoue, Kazuaki Kadonosono","doi":"10.1016/j.ophtha.2025.07.012","DOIUrl":"https://doi.org/10.1016/j.ophtha.2025.07.012","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":9.5,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Environmental Impact of Eye Care Procedures and Visual Healthcare Services: A Systematic Review and Meta-Analysis.","authors":"Ana Paula Oliveira, Clara Martinez-Perez","doi":"10.1016/j.ophtha.2025.08.005","DOIUrl":"10.1016/j.ophtha.2025.08.005","url":null,"abstract":"<p><strong>Topic: </strong>To quantify the environmental impact of eye care procedures (carbon footprint, waste, and energy use) and assess the effectiveness of sustainability strategies.</p><p><strong>Clinical relevance: </strong>Eye care procedures, including cataract surgery, one of the most common globally, generate considerable carbon emissions and waste. Because healthcare accounts for 4.4% of global greenhouse gas emissions, assessing the environmental footprint of ophthalmology is increasingly important. Current practices favor single-use devices and energy-intensive systems, with limited recycling, posing notable sustainability challenges.</p><p><strong>Methods: </strong>A systematic search, registered in PROSPERO (CRD420251036827), was conducted in PubMed, Web of Science, Scopus, and the Cochrane Library without restrictions on publication date or language and completed on April 20, 2025. Eligible studies reported quantitative environmental indicators associated with visual healthcare activities. Data were extracted independently by 2 reviewers following Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020 guidelines and assessed for methodological quality using the Methodological Index for Non-Randomized Studies tool. Continuous variables such as kilograms of carbon dioxide equivalent (CO<sub>2</sub>e) per procedure and waste generation were descriptively summarized, without pooled quantitative synthesis, to highlight interstudy variability. Publication bias was evaluated using funnel plots.</p><p><strong>Results: </strong>From 14 955 initial records, 26 studies met inclusion criteria, with 15 eligible for meta-analysis. Reported carbon footprints varied widely across procedures and settings, with substantial heterogeneity (I² = 100%) precluding the calculation of a meaningful pooled estimate. Cataract surgery exhibited the highest reported footprint (up to 322 kg CO₂e), followed by trabeculectomies (99-126 kg CO₂e) and intravitreal injections (13.7-277 kg CO₂e). Waste generation ranged from 0.05 kg to 3.1 kg per procedure, with a large proportion classified as theoretically recyclable but infrequently recycled because of biosafety restrictions. Consumption per cataract surgery varied between 17.8 and 35.09 kWh, strongly influenced by the source of electricity. Sustainability interventions such as reusable surgical instruments, eco-designed surgical packs, and the reduction in patient visits demonstrated significant reductions in environmental impact, with reusable sets achieving a 96% reduction in emissions after 19 cycles of use. The overall certainty of evidence was judged to be low to very low according to Grading of Recommendations Assessment, Development, and Evaluation (GRADE) assessments.</p><p><strong>Conclusions: </strong>Eye care procedures contribute significantly to healthcare's environmental burden. Targeted sustainability interventions, supported by systemic institutional reforms, offer promising pathw","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":9.5,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144862382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized Sham-Controlled Phase 2/3 Trial of QPI-1007 for Acute Nonarteritic Anterior Ischemic Optic Neuropathy.","authors":"Leonard A Levin, M Tariq Bhatti, Sharon Klier, Rachelle Morgenstern, David Szanto, Neil R Miller, Mark J Kupersmith","doi":"10.1016/j.ophtha.2025.07.039","DOIUrl":"10.1016/j.ophtha.2025.07.039","url":null,"abstract":"<p><strong>Purpose: </strong>Nonarteritic anterior ischemic optic neuropathy (NAION), the most common acute optic neuropathy in patients > 50 years of age, has no proven therapy. We report the results of a phase 2/3 clinical trial studying the safety and efficacy of intravitreal injection of QPI-1007, a small interfering RNA against the apoptotic protein caspase 2, in participants with acute-onset NAION.</p><p><strong>Design: </strong>International, multicenter, double-masked, sham-controlled randomized trial.</p><p><strong>Participants: </strong>Seven hundred twenty-five participants with acute unilateral NAION enrolled within 14 days of visual symptoms.</p><p><strong>Methods: </strong>Intravitreal injection of QPI-1007 into the study eye of a single dose, multiple dose, or sham injection. Participants were randomized in a 1:1:1:1:1 ratio to 5 treatment groups (down to 3 treatment groups after a preplanned interim analysis): 1 intravitreal injection of 1.5 mg, 1 intravitreal injection of 3 mg, 3 bimonthly intravitreal injections of 1.5 mg each, 3 bimonthly intravitreal injections of 3.0 mg each, or sham injection.</p><p><strong>Main outcome measures: </strong>The primary end points were safety and the proportion of patients losing at least 15 Early Treatment Diabetic Retinopathy Study letters of best-corrected visual acuity (BCVA) between day 1 and month 6. Secondary outcome measures were mean change in BCVA and mean change in visual field (VF) sensitivity from day 1 to month 6.</p><p><strong>Results: </strong>At 6 months, no difference was found in the proportion of participants who lost 15 letters or more of BCVA in the multidose groups compared with the sham group. A subanalysis of participants with baseline BCVA of ≤ 60 letters or fewer (Snellen equivalent, ≤ 20/63) demonstrated a significantly lower proportion losing 10 letters of BCVA (P = 0.045 for the 1.5 mg × 3 group and P = 0.0104 for the 3.0 mg × 3 group) compared to sham. Significant prevention of 7-dB loss of VF mean deviation was seen in participants with ≤ 60 letters or fewer at baseline (P = 0.023). No significant differences were found in the frequency of adverse events between groups other than expected side-effects of intravitreal injection.</p><p><strong>Conclusions: </strong>Intravitreal injection of QPI-1007 in eyes with acute NAION was well tolerated. Although the primary outcome measure was not met, significant effects on preserving vision were observed in the subgroup of participants with baseline BCVA of 20/63 or worse.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":9.5,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prevalence of Diabetic Retinopathy in American Indians/Alaska Natives and non-Indigenous Americans: A Systematic Review and Meta-Analysis.","authors":"Caberry W Yu, Keean Nanji, Anubhav Garg, Michele Zaman, Jane Jomy, Abdullah El-Sayes, Catherine Sun, Shreyas Bhat, Mark Phillips, Dena Zeraatkar, Jinhui Ma, Enrico Borrelli, Sunir Garg, David H Steel, Tien Yin Wong, Sobha Sivaprasad, Charles C Wykoff, Varun Chaudhary","doi":"10.1016/j.ophtha.2025.08.004","DOIUrl":"https://doi.org/10.1016/j.ophtha.2025.08.004","url":null,"abstract":"<p><strong>Topic: </strong>To estimate the prevalence of diabetic retinopathy (DR) in adult American Indians / Alaska Natives (AI/AN) and non-AI/AN patients with diabetes.</p><p><strong>Clinical relevance: </strong>Although diabetes mellitus is more prevalent among AI/AN patients compared to non-AI/AN patients, the evidence is inconsistent regarding whether AI/AN patients have a higher prevalence or severity of diabetic retinopathy.</p><p><strong>Methods: </strong>We searched Ovid MEDLINE, EMBASE, and Web of Science Databases from inception until February 23 2025. We included primary studies evaluating the prevalence of DR in Americans with diabetes.The prevalence of a) DR, b) diabetic macular edema (DME), c) proliferative diabetic retinopathy (PDR), d) vision-threatening diabetic retinopathy (VTDR, including DME, PDR, or severe non-proliferative diabetic retinopathy), e) PDR complications were estimated. Meta-analyses were performed using Freeman Tukey double arcsine transformations and random-effects modelling. The Joanna Briggs Institute (JBI) Appraisal Checklist for Prevalence Studies was used to assess risk of bias. GRADE guidelines were used to assess certainty of evidence.</p><p><strong>Results: </strong>Overall, 53 studies of 10 070 617 individuals were included. In the AI/AN and non-AI/AN groups respectively, the pooled prevalence of DR is estimated to be 21% (95% CI: 13%, 30%; GRADE: Low), and 20% (95% CI: 16%, 25%; GRADE: Low), respectively. The prevalence of PDR is estimated to be 3% (95% CI: 1%, 6%; GRADE: Low), and 2% (95% CI: 1%, 4%; GRADE: Low), respectively. The prevalence of DME is estimated to be 3% (95% CI: 2%, 4%; GRADE: Low) and 3% (95% CI: 2%, 4%; GRADE: Low), respectively; and the prevalence of VTDR is estimated to be 3% (95% CI: 1%, 7%; GRADE: Low) and 5% (95% CI: 4%, 7%; GRADE: Low), respectively. High-quality evidence is lacking. Comparative analysis demonstrated there may be no difference in the rate of DR between AI/AN and non-AI/AN patients (OR: 0.67; 95% CI: 0.31, 1.48; GRADE: Low).</p><p><strong>Conclusion: </strong>There appears to be no appreciable difference in the prevalence of DR between AI/AN and non-AI/AN patients, albeit evidence is limited by heterogeneity of studies. The high disease burden highlights that public health strategies are needed equally for AI/AN as well as non-AI/AN patients.</p>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":9.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Efficacy of Ophthalmic Transfers to an Academic Level 1 Trauma Hospital: Diagnostic Accuracy and Intervention Rates.","authors":"Blake Hopkin, Thellea Leveque, Mary Kim, Anna McEvoy, Karine Bojikian, Jennifer T Yu, Shu Feng","doi":"10.1016/j.ophtha.2025.07.037","DOIUrl":"10.1016/j.ophtha.2025.07.037","url":null,"abstract":"<p><strong>Purpose: </strong>To characterize ophthalmic transfers from hospital, emergency department (ED), and urgent care settings to an academic level 1 trauma center and to evaluate the accuracy of transferring diagnoses and rate of intervention after transfer.</p><p><strong>Design: </strong>Retrospective, cross-sectional study.</p><p><strong>Participants: </strong>All patients transferred from outside hospitals, EDs, and urgent care centers accepted by the ophthalmology service at Harborview Medical Center in Seattle, Washington, from February 1, 2022, to January 31, 2023.</p><p><strong>Methods: </strong>Transfer center records were reviewed for patient demographics, transfer facility, method of transport, transfer diagnosis, time from acceptance of transfer to patient arrival, and whether the patient was seen by or discussed with an eye care provider (ophthalmologist or optometrist) before the transfer call. Ophthalmology notes were reviewed for final diagnosis, patient disposition, and procedural interventions within 1 month of transfer. Fisher exact tests were used to compare accuracy of transfer diagnoses and rate of intervention or admission between those with and without an in-person evaluation by an eye care provider before transfer.</p><p><strong>Main outcome measures: </strong>Accuracy of transfer diagnoses and rate of procedural interventions or admission after transfer.</p><p><strong>Results: </strong>Of 685 total transfers, 6.1% of patients received an in-person evaluation by an eye care provider before transfer, and 11.3% were discussed with an eye care provider from the transferring facility. Median (interquartile range [IQR]) travel distance was 30 (16-57) miles, and the median (IQR) time from transfer acceptance to arrival was 216 (158-314) minutes. Transfer diagnoses were accurate in less than half (48.9%) of cases. Half (50.2%) of all transferred patients were discharged from the ED and underwent no procedural intervention within 1 month of transfer. Patients evaluated in-person by an eye care provider before transfer were more likely to have an accurate transfer diagnosis (90.5% vs. 66.3%, P < 0.001) and to require admission or procedural intervention (90.5% vs. 46.8%, P < 0.001).</p><p><strong>Conclusions: </strong>Diagnostic accuracy and likelihood of procedural intervention or admission are higher in patients who undergo an ophthalmic or optometric examination before hospital transfer, suggesting that standardized pretransfer evaluation protocols could enhance diagnostic precision and optimize resource use.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found after the references.</p>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":9.5,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144848192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the Utility of Retinal Nerve Fiber Layer and Ganglion Cell Inner Plexiform Layer OCT Changes to Detect Glaucoma Progression.","authors":"Alex T Pham, Chris Bradley, Jithin Yohannan","doi":"10.1016/j.ophtha.2025.07.040","DOIUrl":"10.1016/j.ophtha.2025.07.040","url":null,"abstract":"<p><strong>Purpose: </strong>Measure and compare the rates of circumpapillary retinal nerve fiber layer (cpRNFL) and macular ganglion cell-inner plexiform layer (mGCIPL) thinning in glaucomatous eyes with and without visual field (VF) progression, across a broad range of disease severity, in a large clinical population.</p><p><strong>Design: </strong>Retrospective, longitudinal study.</p><p><strong>Participants: </strong>A total of 2464 eyes (1605 patients) with longitudinal testing (≥5 reliable cpRNFL, mGCIPL, and VF measurements). All cpRNFL and mGCIPL measurements were within 1 year of a VF test.</p><p><strong>Methods: </strong>We used linear regression to measure rates of cpRNFL and mGCIPL thinning in suspect, mild, moderate, and advanced glaucoma (severity defined by Hodapp-Parrish-Anderson criteria). We compared thinning rates between eyes with and without VF progression (using trend- or event-based criteria). Next, we used logistic mixed-effects models to estimate the impact of cpRNFL and mGCIPL thinning rates on the probability of VF progression. We used general linear hypothesis testing to assess the effect of cpRNFL and mGCIPL thinning rates in each stage of severity.</p><p><strong>Main outcome measures: </strong>Rates of cpRNFL and mGCIPL thinning (μm/year) stratified by disease severity.</p><p><strong>Results: </strong>The cpRNFL and mGCIPL thinning rates were significantly faster in progressing eyes (-1.02 and -1.04 μm/year, respectively) than in nonprogressing eyes (-0.41 and -0.41 μm/year, respectively). Differences between progressors and nonprogressors diminished with worsening disease severity. The effect of cpRNFL and mGCIPL thinning on the probability of VF progression was similar overall (2.4% vs. 2.1% increased probability per 1 μm/year faster rate of thinning) but differed depending on the glaucoma severity. The effect of cpRNFL thinning was greatest in glaucoma suspects but was not statistically significant in advanced glaucoma. In contrast, the effect of mGCIPL thinning was smallest in suspects, increased with worsening disease severity, and was still statistically significant in advanced disease.</p><p><strong>Conclusions: </strong>The cpRNFL and mGCIPL changes serve complementary roles in monitoring glaucoma progression depending on the stage of disease severity. The cpRNFL is more strongly associated with VF progression than mGCIPL in early glaucoma. The mGCIPL is more strongly associated with progression than cpRNFL in later stages of glaucoma.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found after the references.</p>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":9.5,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144848226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema: A Systematic Review and Meta-analysis.","authors":"Keean Nanji, Justin Grad, Amin Hatamnejad, Abdullah El-Sayes, Andrew Mihalache, Mohamed Gemae, Ryan Huang, Mark Phillips, Peter K Kaiser, Marion R Munk, Sunir J Garg, David Sarraf, SriniVas R Sadda, Samantha Fraser-Bell, Dena Zeraatkar, Jinhui Ma, Enrico Borrelli, David H Steel, Sobha Sivaprasad, Charles C Wykoff, Varun Chaudhary","doi":"10.1016/j.ophtha.2025.07.038","DOIUrl":"10.1016/j.ophtha.2025.07.038","url":null,"abstract":"<p><strong>Topic: </strong>To determine effect estimates and certainty of evidence for the associations between baseline OCT biomarkers and (1) patient visual acuity (VA) and (2) changes in VA from baseline to 6, 12, and 24 months after initiation of anti-vascular endothelial growth factor, steroid, or laser treatment for diabetic macular edema.</p><p><strong>Clinical relevance: </strong>Understanding the prognostic value conferred by biomarkers can help predict disease activity and inform treatment decisions.</p><p><strong>Methods: </strong>This review was registered in the International Prospective Register of Systematic Reviews (identifier, CRD42023487798). Ovid MEDLINE, EMBASE, and CENTRAL databases were searched. Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) guidelines informed certainty of evidence.</p><p><strong>Results: </strong>Twenty-eight reports from 27 studies evaluating 75 biomarkers were included. No biomarker with at least a moderate certainty was associated with improved VA or change in VA. Results are reported in Early Treatment Diabetic Retinopathy Study letters. Five biomarkers were associated with reduced VA at 2 or more time points with moderate certainty: (1) hyperreflective retinal foci (HRF; 6 months, -6.5 [95% confidence interval (CI), -10.4 to -2.6]; 12 months, -7.3 [95% CI, -11.6 to -3.0], (2) hyperreflective choroidal foci (HCF; 6 months, -7.3 [95% CI, -13.3 to -1.3]; 12 months, -7.5 [95% CI, -11.9 to -3.0], (3) disorganization of retinal inner layers (DRIL; 6 months, -6.0 [95% CI, -11.7 to -0.3]; 12 months, -7.3 [95% CI, -12.8 to -1.7], (4) disrupted ellipsoid zone (EZ) or external limiting membrane (ELM; 6 months, -9.7 [95% CI, -15.4 to -3.9]; 12 months, -7.5 [95% CI, -11.9 to -3.0]; 12 months isolated EZ disruption, -5.4; [95% CI, -9.2 to -1.6] ; 24 months, -9.0 [95% CI, -14.3 to -3.6], and (5) disrupted cone outer segment termination (COST) line (12 months, -8.5 [95% CI, -13.5 to -3.5]; 24 months, -8.8 [95% CI, -14.0 to -3.6].</p><p><strong>Discussion: </strong>Baseline HRF, HCF, DRIL, disrupted EZ or ELM, and disrupted COST lines were associated with worse VA at 2 or more time points with moderate certainty of evidence. Greater standardization in biomarker classification and better control of confounding variables are needed.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":9.5,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144848193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatio-Temporal Optical Phase Kit for Myopia Control: Stage 1 Results from a Randomized Controlled Clinical Trial in Chinese Children.","authors":"Cathleen Fedtke, Zhi Chen, Daniel Tilia, Lihua Li, Xiaoqin Chen, Klaus Ehrmann, Karen Lahav-Yacouel, Darrin Falk, Fabian Conrad, Kah Ooi Tan, Ravi C Bakaraju","doi":"10.1016/j.ophtha.2025.08.001","DOIUrl":"10.1016/j.ophtha.2025.08.001","url":null,"abstract":"<p><strong>Purpose: </strong>The Spatio-Temporal Optical Phase (S.T.O.P.; nthalmic Pty Ltd) kit provides a dynamic optical cue using optical films on single-vision spectacles. This study assessed the efficacy of 2 S.T.O.P. kits (kits 1 and 2) in reducing myopia progression against single-vision spectacles without optical films (control group).</p><p><strong>Design: </strong>Prospective, multi-site, parallel-group, double-masked randomized controlled trial.</p><p><strong>Participants: </strong>One hundred fifty-five participants completed the study (n = 50, 52, and 53 in the kit 1, kit 2, and control groups, respectively).</p><p><strong>Methods: </strong>One hundred sixty eligible children 6 to 14 years of age with myopia of between -0.75 diopter (D) and -5.00 D and astigmatism of 1.50 D or less were enrolled at the Fudan University Eye and ENT Hospital and Tianjin Eye Hospital between December 2023 and February 2025. Participants were assigned randomly to wear kit 1, kit 2, or no optical films (control group). Axial length (AL) was measured at baseline, at dispensing, and at 1, 4, and 6 months after dispensing. Cycloplegic autorefraction was measured at baseline and 6 months after dispensing. Differences between the control and each test group for changes in AL and spherical-equivalent cycloplegic autorefraction were analyzed using linear mixed models in the intention-to-treat population. Differences in visual acuity (VA) and subjective ratings were also assessed.</p><p><strong>Main outcome measures: </strong>Change in AL from dispensing to the 6-month visit and change in spherical-equivalent cycloplegic autorefraction from baseline to the 6-month visit.</p><p><strong>Results: </strong>After 6 months, both S.T.O.P. kit groups showed significantly less change in AL than the control group. The estimated least-square mean differences (95% confidence intervals) compared with control for AL were: kit 1, -0.091 (-0.131 to -0.051) mm and kit 2, -0.090 (-0.130 to -0.050) mm and for spherical-equivalent cycloplegic autorefraction were: kit 1, 0.135 (0.003 to 0.268) D and kit 2, 0.134 (0.001 to 0.267) D. No significant differences were found between groups for VA or any subjective rating.</p><p><strong>Conclusions: </strong>Both S.T.O.P. kit groups showed significantly less myopia progression compared with the control group while maintaining good visual performance. The S.T.O.P. kit's dynamic approach represents a promising strategy for myopia management.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":9.5,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant Transformation of a Kissing Nevus.","authors":"Yaoming Liu, Rong Lu","doi":"10.1016/j.ophtha.2025.07.002","DOIUrl":"https://doi.org/10.1016/j.ophtha.2025.07.002","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":9.5,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144789649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TMEM53 Gene Mutation Combined with Uniparental Diploidy of Chromosome 1 Causes Binocular Optic Atrophy Secondary to Craniotubular Dysplasia, Ikegawa Type.","authors":"Meng Gao, Gang Sun, YingYing Wang","doi":"10.1016/j.ophtha.2025.07.003","DOIUrl":"https://doi.org/10.1016/j.ophtha.2025.07.003","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":9.5,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144789650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}